Journal of Oncology / 2012 / Article / Tab 1 / Review Article
Ovarian Cancer: Opportunity for Targeted Therapy Table 1 Potential targets of therapy in ovarian cancer.
Targets Inhibitors Studies NCI study GOG 218 VEGF Bevacizumab Phase III [49 ] ICON 7 GOG 213 OCEANS VEGF TKI Sunitinib Phase II NCT00979992 NCT00768144 NCT00388037 Vatalanib Phase I (+doce) NCT00268918 Sorafenib Phase II (+carb/pacli) NCT00390611 Phase II (+topo) NCT01047891 Phase II NCT00522301 Phase II (+bev) NCT00436215 Phase II [36 ] NCT00093626 Phase II (+carb/pacli) NCT00096200 Vandetanib Phae I/II (+bortezomib) NCT00923247 Phase II NCT00445549 Phase II(+/− doce) NCT00872989 Cediranib Phase I/II(+olaparib) NCT01116648 Phase II NCT00275028 Phase II (+temsirolimus) NCT01065662 Pazopanib Phase I/II (+cyclophosphamide) NCT01238770 Phase II NCT01262014 Phase I/II [37 ] NCT01035658 Phase II NCT00281632 Phase III NCT00866697 Vargatef Phase I (+everolimus) Pending AMG 706 Phase II NCT00574951 VEGF TRAP Aflibercept Phase II NCT00327171 Phase II (+doce) NCT00436501 PI3K-PTEN-Akt-mTOR pathway Temsirolimus Phase I (+lip Doxo) NCT00982631 Phase II NCT00926107 Phase II (carb/pacli) NCT01196429 Phase II NCT00429793 Phase I/II(+bev) NCT01010126 Everolimus Phase II (+bev) NCT01031381 Phase II (+/− bev) NCT00886691 Phase II (+lip doxo) NCT01281514 Ridaforolimus Phase I (+carb/pacli) NCT01256268 EGFR Cetuximab Phase II (carb/pacli) NCT00063401/ Phase II (+carb) NCT00086892 Erlotinib Phase II (+bev) [38 ] NCT00130520 Phase II (+topo) NCT01003938 Phase I/II (+carb/pacli) NCT00217529 Phase II (+carb) NCT00030446 Phase II (+bev after carb/pacli/bev) NCT00520013 Lapatinib Phase II (+topo) [39 ] NCT00436644 Phase II NCT00113373 Phase I/II (+carb/pacli) NCT00316407 HER2 Trastuzumab Phase II [40 ] Pertuzumab Phase II NCT00058552 Phase II (+gemcitabine) NCT00096993 Lapatinib See above PARP ABT 888 Phase II (+temoz versus lip doxo) NCT01113957 Phase II (+cyclophosphamide) NCT01306032 Phase I/II (+topo) NCT01012817 Phase I (+carb/pacli/bev) NCT00989651 Olaparib Phase II (+carb/pacli) NCT01081951 Phase I (+carb) NCT00647062 Phase II NCT00679783 Phase II NCT00494442 Phase II (versus lip doxo) NCT00628251 Phase II NCT00753545 Phase II NCT01033123 Iniparib* Phase II (carb/gemcitabine) NCT01033292 Phase II NCT00677079 Epigenetic Decitabine Phase II (+carb) NCT00477386 Phase I (+doxorubicin/vaccine) NCT00887796 Belinostat Phase I/II (+carb or pacli) NCT00421889 MAPK/RAF/MEK pathway Cabozantinib Phase I NCT00940225 HMGA2 Let-7 microRNA Preclinical
*Iniparib as a true PARP inhibitor is currently under investigation.
